Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 26, 2016 - Issue 7
Submit an article Journal homepage
1,198
Views
54
CrossRef citations to date
0
Altmetric
Review

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update

Paula MoralesInstituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain
,
Laura Hernandez-FolgadoInstituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain
,
Pilar GoyaInstituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain
&
Nadine JagerovicInstituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, SpainCorrespondence[email protected]
Pages 843-856 | Received 18 Mar 2016, Accepted 19 May 2016, Published online: 07 Jun 2016

Citations (54)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Paula Morales & Nadine Jagerovic. (2020) Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opinion on Drug Discovery 15:8, pages 917-930.
Read now

Articles from other publishers (53)

Si-jing Hu, Gang Cheng, Gao-ce Chen, Hao Zhou, Qi Zhang, Qi-ming Zhao, Chen-xia Lian, Zi-hui Zhao, Quan-long Zhang, Ting Han, Qiao-yan Zhang & Lu-ping Qin. (2023) Cannabinoid receptors type 2: Function and Development in Agonist Discovery from synthetic and natural sources with Applications for the Therapy of Osteoporosis. Arabian Journal of Chemistry, pages 105536.
Crossref
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, Uwe Grether, Allyn C. Howlett, Tian Hua, Alexandros Makriyannis, Daniele Piomelli, Natsuo Ueda & Mario van der Stelt. (2023) Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years. Pharmacological Reviews 75:5, pages 885-958.
Crossref
Pinaki Bhattacharjee & Malliga R. Iyer. (2023) Rational Design, Synthesis, and Evaluation of Fluorescent CB2 Receptor Ligands for Live-Cell Imaging: A Comprehensive Review. Pharmaceuticals 16:9, pages 1235.
Crossref
Yaping Zheng, Pei Li, Jie Shen, Kailin Yang, Xinyan Wu, Yue Wang, Yu-he Yuan, Peigen Xiao & Chunnian He. (2023) Comprehensive comparison of different parts of Paeonia ostii, a food-medicine plant, based on untargeted metabolomics, quantitative analysis, and bioactivity analysis. Frontiers in Plant Science 14.
Crossref
Geovane Marcos Guimarães de Souza & Marcus Vinicius Dias-Souza. (2023) Neuropharmacology of endogenous, synthetic and phytocannabinoids for pain management. Physiology and Pharmacology 27:2, pages 100-115.
Crossref
Alexandru Vasincu, Răzvan-Nicolae Rusu, Daniela-Carmen Ababei, Monica Neamțu, Oana Dana Arcan, Ioana Macadan, Sorin Beșchea Chiriac, Walther Bild & Veronica Bild. (2023) Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity. Biomedicines 11:6, pages 1667.
Crossref
Valeria Gasperi, Tatiana Guzzo, Alessandra Topai, Nicola Gambacorta, Fulvio Ciriaco, Orazio Nicolotti & Mauro Maccarrone. (2023) Recent Advances on Type-2 Cannabinoid (CB 2 ) Receptor Agonists and their Therapeutic Potential . Current Medicinal Chemistry 30:12, pages 1420-1457.
Crossref
Jinshan Nan, Jingming Liu, Guifeng Lin, Shanshan Zhang, Anjie Xia, Pei Zhou, Yangli Zhou, Jiahao Zhang, Jinlong Zhao, Shiyu Zhang, Chong Huang, Yifei Wang, Qian Hu, Junxian Chen, Mingli Xiang, Xin Yang & Shengyong Yang. (2023) Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain. Journal of Medicinal Chemistry 66:5, pages 3460-3483.
Crossref
Gamal A. Mohamed, Abdelsattar M. Omar, Dana F. AlKharboush, Mona A. Fallatah, Ikhlas A. Sindi, Dina S. El-Agamy & Sabrin R. M. Ibrahim. (2023) Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists. Molecules 28:4, pages 1761.
Crossref
Adam Stasiulewicz, Anna Lesniak, Magdalena Bujalska-Zadrożny, Tomasz Pawiński & Joanna I. Sulkowska. (2023) Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation. Journal of Chemical Information and Modeling 63:3, pages 1012-1027.
Crossref
María Gómez-Cañas, Paula Morales, Valentina Satta, Carmen Rodríguez-Cueto, Concepción García & Onintza Sagredo. (2022) Editorial: Cannabinoids as potential treatment for neurological diseases. Frontiers in Neuroscience 16.
Crossref
Jay Shah & Olga Fermo. (2022) Review of systemic and syndromic complications of cannabis use: A review. Medicine 101:49, pages e32111.
Crossref
Grace Clouse, Samantha Penman, Michael Hadjiargyrou, David E. Komatsu & Panayotis K. Thanos. (2022) Examining the role of cannabinoids on osteoporosis: a review. Archives of Osteoporosis 17:1.
Crossref
Reem Smoum, Uwe Grether, Meliha Karsak, Andrea J. Vernall, Frank Park, Cecilia J. Hillard & Pal Pacher. (2022) Editorial: Therapeutic potential of the cannabinoid CB2 receptor. Frontiers in Pharmacology 13.
Crossref
Anthony S. Ferranti & Daniel J. Foster. (2022) Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Frontiers in Neuroscience 16.
Crossref
Francesca Seghetti, Silvia Gobbi, Federica Belluti, Angela Rampa & Alessandra Bisi. (2022) Interplay Between Endocannabinoid System and Neurodegeneration: Focus on Polypharmacology. Current Medicinal Chemistry 29:28, pages 4796-4830.
Crossref
Gabriele Gallo Afflitto, Francesco Aiello, Damiana Scuteri, Giacinto Bagetta & Carlo Nucci. (2022) CB1R, CB2R and TRPV1 expression and modulation in in vivo, animal glaucoma models: A systematic review. Biomedicine & Pharmacotherapy 150, pages 112981.
Crossref
Xiaoyan Lin, Zhili Xu, Lawrence Carey, Julian Romero, Alexandros Makriyannis, Cecilia J. Hillard, Elizabeth Ruggiero, Marilyn Dockum, George Houk, Ken Mackie, Phillip J. Albrecht, Frank L. Rice & Andrea G. Hohmann. (2022) A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain 163:5, pages 834-851.
Crossref
Jakub Mlost, Przemysław Kac, Marta Kędziora & Katarzyna Starowicz. (2022) Antinociceptive and chondroprotective effects of prolonged β-caryophyllene treatment in the animal model of osteoarthritis: Focus on tolerance development. Neuropharmacology 204, pages 108908.
Crossref
Si-Jing Hu, Gang Cheng, Hao Zhou, Qi Zhang, Quan-Long Zhang, Yang Wang, Yi Shen, Chen-Xia Lian, Xue-Qin Ma, Qiao-Yan Zhang & Lu-Ping Qin. (2022) Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects. Molecules 27:3, pages 702.
Crossref
Aboagyewaah Oppong-Damoah, Brenda Marie Gannon & Kevin Sean Murnane. (2022) The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?. CNS & Neurological Disorders - Drug Targets 21:1, pages 3-13.
Crossref
Jiacheng Du, Menglei Xu, Fanchen Kong, Pengfei Zhu, Yubo Mao, Yijie Liu, Hong Zhou, Zhongchen Dong, Zilin Yu, Tong Du, Ye Gu, Xiexing Wu, Dechun Geng & Haiqing Mao. (2022) CB2R Attenuates Intervertebral Disc Degeneration by Delaying Nucleus Pulposus Cell Senescence through AMPK/GSK3β Pathway. Aging and disease 13:2, pages 552.
Crossref
Paweł Marzęda, Małgorzata Drozd, Paula Wróblewska-Łuczka & Jarogniew J. Łuszczki. (2021) Cannabinoids and their derivatives in struggle against melanoma. Pharmacological Reports 73:6, pages 1485-1496.
Crossref
Chunming Zhao, Yangyi Dong, Jialin Liu, Hongxing Cai, Zhouru Li, Xiaoming Sun, Wenjiang Yin, Jingyuan Ma, Hongmei Liu & Shanshan Li. (2021) An enzyme-responsive Gp1a-hydrogel for skin wound healing. Journal of Biomaterials Applications 36:4, pages 714-721.
Crossref
Astrid Coronado-Álvarez, Karen Romero-Cordero, Lorena Macías-Triana, Agnes Tatum-Kuri, Alba Vera-Barrón, Henning Budde, Sérgio Machado, Tetsuya Yamamoto, Claudio Imperatori & Eric Murillo-Rodríguez. (2021) The synthetic CB1 cannabinoid receptor selective agonists: Putative medical uses and their legalization. Progress in Neuro-Psychopharmacology and Biological Psychiatry 110, pages 110301.
Crossref
Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N. Goyal, Niraj Kumar Jha & Shreesh Ojha. (2021) Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist. Frontiers in Pharmacology 12.
Crossref
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré & Uwe Grether. (2021) Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. Pharmaceutical Patent Analyst 10:3, pages 111-163.
Crossref
Savanah L. Saldaña-Shumaker, Alexander J. Grenning & Christopher W. Cunningham. (2021) Modern approaches to the development of synthetic cannabinoid receptor probes. Pharmacology Biochemistry and Behavior 203, pages 173119.
Crossref
Filippo Basagni, Michela Rosini & Michael Decker. (2020) Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes. ChemMedChem 15:15, pages 1374-1389.
Crossref
Dongchen An, Steve Peigneur, Louise Antonia Hendrickx & Jan Tytgat. (2020) Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. International Journal of Molecular Sciences 21:14, pages 5064.
Crossref
Jiaojiao Li, Jing Ji, Ruibo Xu & Zhengfu Li. (2019) Indole compounds with N -ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation . MedChemComm 10:11, pages 1935-1947.
Crossref
Pedro Melgar-Lesmes, Meritxell Perramon & Wladimiro Jiménez. (2019) Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. Cells 8:11, pages 1311.
Crossref
Aya E. Ghonim, Alessia Ligresti, Alessandro Rabbito, Ali Mokhtar Mahmoud, Vincenzo Di Marzo, Noha A. Osman & Ashraf H. Abadi. (2019) Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties. European Journal of Medicinal Chemistry 180, pages 154-170.
Crossref
Juan A. Páez & Nuria E. Campillo. (2019) Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases. Current Medicinal Chemistry 26:18, pages 3300-3340.
Crossref
Jiang Wu, Mark Hocevar, Bihua Bie, Joseph F. Foss & Mohamed Naguib. (2019) Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. The Journal of Pain 20:5, pages 501-514.
Crossref
Alessandra Bisi, Alì Mokhtar Mahmoud, Marco Allará, Marina Naldi, Federica Belluti, Silvia Gobbi, Alessia Ligresti & Angela Rampa. (2019) Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities. ACS Medicinal Chemistry Letters 10:4, pages 596-600.
Crossref
Sameek Singh, Caitlin R. M. Oyagawa, Christa Macdonald, Natasha L. Grimsey, Michelle Glass & Andrea J. Vernall. (2019) Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor. ACS Medicinal Chemistry Letters 10:2, pages 209-214.
Crossref
Claudia Mugnaini, Alessandro Rabbito, Antonella Brizzi, Nastasja Palombi, Stefania Petrosino, Roberta Verde, Vincenzo Di Marzo, Alessia Ligresti & Federico Corelli. (2019) Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease. European Journal of Medicinal Chemistry 161, pages 239-251.
Crossref
Caitlin R. M. Oyagawa, Sara M. de la Harpe, Yurii Saroz, Michelle Glass, Andrea J. Vernall & Natasha Lillia Grimsey. (2018) Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. Frontiers in Pharmacology 9.
Crossref
Paula Morales, Pilar Goya & Nadine Jagerovic. (2018) Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism. Biochemical Pharmacology 157, pages 8-17.
Crossref
C Sagnelli, C Uberti-Foppa, H Hasson, G Bellini, C Minichini, S Salpietro, E Messina, D Barbanotti, M Merli, F Punzo, N Coppola, A Lazzarin, E Sagnelli & F Rossi. (2018) In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection . HIV Medicine 19:9, pages 597-604.
Crossref
Vincenzo Di Marzo. (2018) New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery 17:9, pages 623-639.
Crossref
Bihua Bie, Jiang Wu, Joseph F. Foss & Mohamed Naguib. (2018) An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Current Opinion in Anaesthesiology 31:4, pages 407-414.
Crossref
Giulio Ragusa, Serena Bencivenni, Paula Morales, Tyra Callaway, Dow P. Hurst, Battistina Asproni, Stefania Merighi, Giovanni Loriga, Gerard A. Pinna, Patricia H. Reggio, Stefania Gessi & Gabriele Murineddu. (2018) Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands. ChemMedChem 13:11, pages 1102-1114.
Crossref
Wei Tuo, Mélanie Bollier, Natascha Leleu-Chavain, Lucas Lemaire, Amélie Barczyk, Xavier Dezitter, Frédérique Klupsch, Fabien Szczepanski, John Spencer, Philippe Chavatte & Régis Millet. (2018) Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping. European Journal of Medicinal Chemistry 146, pages 68-78.
Crossref
Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Xiuwen Zhu, Jayant Thatte, Michelle Solomon, Ibragim Gaidarov, David J. Unett, Woo Hyun Yoon, Jeremy Barden, Abu Sadeque, Amin Usmani, Chuan Chen, Graeme Semple, Andrew J. Grottick, Hussein Al-Shamma, Ronald Christopher & Robert M. Jones. (2017) Discovery of APD371: Identification of a Highly Potent and Selective CB 2 Agonist for the Treatment of Chronic Pain . ACS Medicinal Chemistry Letters 8:12, pages 1309-1313.
Crossref
Andrea Martella, Huub Sijben, Arne C. Rufer, Uwe Grether, Juergen Fingerle, Christoph Ullmer, Thomas Hartung, Adriaan P. IJzerman, Mario van der Stelt & Laura H. Heitman. (2017) A Novel Selective Inverse Agonist of the CB 2 Receptor as a Radiolabeled Tool Compound for Kinetic Binding Studies . Molecular Pharmacology 92:4, pages 389-400.
Crossref
Zhen Zhang, Chunfeng Yang, Xinlun Dai, Yu Ao & Yumei Li. (2017) Inhibitory effect of trans-caryophyllene (TC) on leukocyte-endothelial attachment. Toxicology and Applied Pharmacology 329, pages 326-333.
Crossref
Brian J. Piper, Monica L. Beals, Alexander T. Abess, Stephanie D. Nichols, Maurice W. Martin, Catherine M. Cobb & Rebecca M. DeKeuster. (2017) Chronic pain patients' perspectives of medical cannabis. Pain 158:7, pages 1373-1379.
Crossref
Rareş-Petru Moldovan, Kristin Hausmann, Winnie Deuther-Conrad & Peter Brust. (2017) Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands. ACS Medicinal Chemistry Letters 8:5, pages 566-571.
Crossref
Anna-Maria Szczesniak, Richard F. Porter, James T. Toguri, Joanna Borowska-Fielding, Simon Gebremeskel, Anuja Siwakoti, Brent Johnston, Christian Lehmann & Melanie E.M. Kelly. (2017) Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy. Neuropharmacology 113, pages 627-638.
Crossref
Giulio Ragusa, María Gómez-Cañas, Paula Morales, Carmen Rodríguez-Cueto, María R. Pazos, Battistina Asproni, Elena Cichero, Paola Fossa, Gerard A. Pinna, Nadine Jagerovic, Javier Fernández-Ruiz & Gabriele Murineddu. (2017) New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. European Journal of Medicinal Chemistry 127, pages 398-412.
Crossref
Jerome BouazizAlexandra Bar OnDaniel S. SeidmanDavid Soriano. (2017) The Clinical Significance of Endocannabinoids in Endometriosis Pain Management. Cannabis and Cannabinoid Research 2:1, pages 72-80.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.